Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.

Michael Marco,Lihong Zhou,Sujata Patil,Jorge E. Marcet,Madhulika G. Varma,Samuel Oommen,Peter A. Cataldo,Steven R. Hunt,Anjali S. Kumar,Daniel O. Herzig,Alessandro Fichera,Blase N. Polite,Neil Hyman,Charles A. Ternent,Michael J. Stamos,Alessio Pigazzi,David W. Dietz,Yuliya Yakunina,Raphael Pelossof,Julio Garcia-Aguilar

Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.

2018

BACKGROUND:Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response.OBJECTIVE:The purpose of

Keywords:

Folinic acid
Surgery
Medicine
Fluorouracil
Oncology
Oxaliplatin
Chemoradiotherapy
Colorectal cancer
Internal medicine
Chemotherapy
in patient
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations